-
Mashup Score: 4Antibody–Exatecan Conjugates with a Novel Self-immolative Moiety Overcome Resistance in Colon and Lung Cancer - 1 year(s) ago
An antibody–drug conjugate (ADC) class that combines a novel self-immolative T moiety and the topoisomerase I inhibitor exatecan displays higher therapeutic indices to overcome intrinsic or induced tumor resistance to current ADCs while also improving ADC stability to limit off-target toxicities.
Categories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Antibody-exatecan conjugates with a novel self-immolative moiety overcome resistance in colon and lung cancer - 1 year(s) ago
Abstract. Antibody-drug conjugates (ADCs) using DNA Topoisomerase I inhibitor DXd/SN-38 have transformed cancer treatment, yet more effective ADCs are needed for overcoming resistance. We have designed an ADC class using a novel self-immolative T moiety for traceless conjugation and release of exatecan, a more potent Topoisomerase I inhibitor with less sensitivity to multidrug (MDR) resistance….
Categories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Antibody-Exatecan Conjugates with a Novel Self-Immolative Moiety Overcome Resistance in #ColonCancer and #LungCancer, by Weining Weng, Tao Meng, Shu-Hui Liu, Wenhao Hu, Xun Meng et al. https://t.co/4QYuAWon7A #AntibodyDrugConjugate https://t.co/8DIagibIVH
-
-
Mashup Score: 7Emerging Combinations for Triple-Positive Breast Cancer - 3 year(s) ago
An overview of various trials investigating combination approaches as frontline therapy for triple-positive breast cancer and considerations for when to use chemotherapy and bring endocrine therapy into treatment.
Source: OncLiveCategories: Latest Headlines, Oncologists1Tweet-
SCI leader Mark Pegram discusses the latest advances in metastatic #HER2 positive #breastcancer treatment, including #antibodydrugconjugate and #tyrosinekinaseinhibitor therapies. https://t.co/2VzyaRAa42 #bcsm
-
-
Mashup Score: 8
Sacituzumab Govitecan (SG), the first antibody drug conjugate (ADC) approved for triple-negative breast cancer (TNBC), incorporates the anti-TROP2 antibody hRS7 conjugated to a topoisomerase-1 (TOP1) inhibitor payload. We sought to identify mechanisms of SG resistance through RNA and whole-exome sequencing of pre-treatment and post-progression specimens. One patient exhibiting de novo progression…
Source: Cancer DiscoveryCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Parallel genomic alterations of antigen and payload targets mediate polyclonal acquired clinical resistance to sacituzumab govitecan in triple-negative #breastcancer by Leif Ellisen, @ABhealer108 and colleagues @MGHCancerCenter #antibodydrugconjugate #bcsm https://t.co/gTcqqnFyvG https://t.co/s7KwHWBJgd
-
-
Mashup Score: 4
Currently, the only approved treatments for gastrointestinal stromal tumor (GIST) are tyrosine kinase inhibitors (TKIs), which eventually lead to development of secondary resistance mutations in KIT or PDGFRA and disease progression. Herein, we identified G protein-coupled receptor 20 (GPR20) as a novel non-TK target in GIST, developed new GPR20 immunohistochemistry, assessed GPR20 expression in…
Source: Cancer DiscoveryCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
ICYMI: Identification and Therapeutic Targeting of GPR20, Selectively Expressed in Gastrointestinal Stromal Tumors, with DS-6157a, a First-In-Class #AntibodyDrugConjugate. @DaiichiSankyo #GIST #ADC https://t.co/lNVz2x61Lg
-
-
Mashup Score: 4
Currently, the only approved treatments for gastrointestinal stromal tumor (GIST) are tyrosine kinase inhibitors (TKIs), which eventually lead to development of secondary resistance mutations in KIT or PDGFRA and disease progression. Herein, we identified G protein-coupled receptor 20 (GPR20) as a novel non-TK target in GIST, developed new GPR20 immunohistochemistry, assessed GPR20 expression in…
Source: Cancer DiscoveryCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Recently published #OnlineFirst: Identification and Therapeutic Targeting of GPR20, Selectively Expressed in Gastrointestinal Stromal Tumors, with DS-6157a, a First-In-Class #AntibodyDrugConjugate. @DaiichiSankyo #GIST #ADC https://t.co/pUNXIfmmAv https://t.co/QuuMwTdWtc
-
-
Mashup Score: 8Immunomedics Announces Positive Results from Phase 3 ASCENT Study of TRODELVYTM - Immunomedics - 4 year(s) ago
Trodelvy significantly improved progression-free survival (PFS) and overall survival (OS) in previously-treated brain metastasis negative patients with advanced mTNBC The safety profile of Trodelvy was consistent with the FDA-approved label and no new safety signals were observed Trodelvy is the first antibody-drug conjugate (ADC) shown to improve…
Source: ImmunomedicsCategories: Hem/Oncs, Latest HeadlinesTweet-
Press release of the #ASCENT trial announcing positive results with use of the #AntibodyDrugConjugate #sacituzumabgovitecan in patients with advanced #TripleNegative #BreastCancer #TNBC already exposed to 2 prior therapies #bcsm #immunomedics #OncoAlert https://t.co/52ff22IZQA
-
In the April issue of Cancer Discovery— Antibody-Exatecan Conjugates with a Novel Self-Immolative Moiety Overcome Resistance in #ColonCancer and #LungCancer, by Weining Weng, Tao Meng, Shu-Hui Liu, Wenhao Hu, Xun Meng et al. https://t.co/JkHjwxihfC #AntibodyDrugConjugate https://t.co/npEME7pnh2